ASSOCIATION OF TRANSFORMING GROWTH FACTOR-Β (TGF-Β) WITH LIVER FIBROSIS SEVERITY IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
Abstract
Background Liver fibrosis represents the most important determinant of long-term prognosis in metabolic dysfunction-associated fatty liver disease (MAFLD). Transforming Growth Factor-β (TGF-β) is considered one of the principal cytokines involved in hepatic fibrogenesis.
Aim To evaluate serum TGF-β levels in patients with different stages of MAFLD and determine their relationship with liver fibrosis severity.
References
1. Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.
2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
3. Friedman SL. Liver fibrosis — From bench to bedside. Journal of Hepatology. 2003;38(Suppl 1)–S53.
4. Friedman SL. Hepatic fibrosis — Overview. Toxicology. 2008;254(3):120–129.
5. Bataller R, Brenner DA. Liver fibrosis. Journal of Clinical Investigation. 2005;115(2):209–218.
6. Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Advanced Drug Delivery Reviews. 2017;121:27–42.
